Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04974359 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04974359 is a Phase 1 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 3 participants.
The verdict
NCT04974359, a Phase 1 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effect of Lu AG06466 on the body in participants with fibromyalgia by assessing pain levels, brain signal changes, and psychiatric (mental) assessments.
Interventions
- DRUG Placebo
- DRUG Lu AG06466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2022-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04974359
The ClinicalTrials.gov registry entry for NCT04974359 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04974359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04974359 about?
NCT04974359 is a clinical study titled "A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia". The purpose of this study is to find out the effect of Lu AG06466 on the body in participants with fibromyalgia by assessing pain levels, brain signal changes, and psychiatric (mental) assessments.
What is the current status of trial NCT04974359?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-06-24. Estimated completion is 2022-01-26.
What interventions are being tested in trial NCT04974359?
The interventions under investigation include: Placebo (DRUG), Lu AG06466 (DRUG).
Who is sponsoring clinical trial NCT04974359?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.